Akeso (4RY) Stock Overview
A biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 4RY from our risk checks.
4RY Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Akeso, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$12.60 |
| 52 Week High | HK$19.30 |
| 52 Week Low | HK$6.75 |
| Beta | 0.25 |
| 1 Month Change | 4.13% |
| 3 Month Change | 0% |
| 1 Year Change | 68.00% |
| 3 Year Change | 123.01% |
| 5 Year Change | 129.09% |
| Change since IPO | 284.56% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4RY | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -4.5% | -1.5% | -1.0% |
| 1Y | 68.0% | -10.3% | 10.1% |
Return vs Industry: 4RY exceeded the German Biotechs industry which returned -10.1% over the past year.
Return vs Market: 4RY exceeded the German Market which returned 10.1% over the past year.
Price Volatility
| 4RY volatility | |
|---|---|
| 4RY Average Weekly Movement | 6.8% |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 4RY has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 4RY's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 3,529 | Michelle Xia | www.akesobio.com |
Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, liver cancer, and esophageal cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell carcinoma, breast cancer, colorectal cancer, and pancreatic cancer. It is also developing AK117, a CD47 monoclonal antibody to treat myelodysplastic syndrome, acute myeloid leukemia, and recurrent or refractory classical Hodgkin lymphoma; AK109, a PD-1 monoclonal antibody to treat G/GEJ patients; penpulimab, a PD-1 for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC); and tagitanlimab, a PD-L1 for treating recurrent or metastatic NPC.
Akeso, Inc. Fundamentals Summary
| 4RY fundamental statistics | |
|---|---|
| Market cap | €11.64b |
| Earnings (TTM) | -€102.77m |
| Revenue (TTM) | €304.99m |
Is 4RY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4RY income statement (TTM) | |
|---|---|
| Revenue | CN¥2.51b |
| Cost of Revenue | CN¥520.68m |
| Gross Profit | CN¥1.99b |
| Other Expenses | CN¥2.84b |
| Earnings | -CN¥846.01m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.92 |
| Gross Margin | 79.26% |
| Net Profit Margin | -33.70% |
| Debt/Equity Ratio | 71.2% |
How did 4RY perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/25 19:28 |
| End of Day Share Price | 2026/01/23 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Akeso, Inc. is covered by 39 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rebecca Liang | Bernstein |
| Ethan Cui | BofA Global Research |
| Shun Kei Law | CCB International Securities Limited |